Sonia Iyer

机构：AstraZeneca (Brazil), AstraZeneca (Japan), AstraZeneca (United States) · ORCID：0000-0003-3840-5583

发表论文 101 篇 · 总被引 1173 次 · h-index 18

代表论文

• Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial (2024 · Nature Medicine · 被引 134)
• The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment (2024 · Nature Communications · 被引 64)
• KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer (2025 · Cancer Cell · 被引 24)
• Inflammation awakens dormant cancer cells by modulating the epithelial–mesenchymal phenotypic state (2025 · Proceedings of the National Academy of Sciences · 被引 17)
• Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer: Longitudinal changes in circulating tumor DNA. (2025 · Journal of Clinical Oncology · 被引 12)
• Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study (2024 · Clinical Cancer Research · 被引 11)